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Abstract
Background: The mechanisms behind formation and filling of intracranial arachnoid cysts (AC) are poorly
understood. The aim of this study was to evaluate AC fluid by proteomics to gain further knowledge about ACs.
Two goals were set: 1) Comparison of AC fluid from individual patients to determine whether or not temporal AC
is a homogenous condition; and 2) Evaluate the protein content of a pool of AC fluid from several patients and
qualitatively compare this with published protein lists of cerebrospinal fluid (CSF) and plasma.
Methods: AC fluid from 15 patients with temporal AC was included in this study. In the AC protein comparison
experiment, AC fluid from 14 patients was digested, analyzed by LC-MS/MS using a semi-quantitative label-free
approach and the data were compared by principal component analysis (PCA) to gain knowledge of protein
homogeneity of AC. In the AC proteome evaluation experiment, AC fluid from 11 patients was pooled, digested, and
fractionated by SCX chromatography prior to analysis by LC-MS/MS. Proteins identified were compared to
published databases of proteins identified from CSF and plasma. AC fluid proteins not found in these two
databases were experimentally searched for in lumbar CSF taken from neurologically-normal patients, by a targeted
protein identification approach called MIDAS (Multiple Reaction Monitoring (MRM) initiated detection and
sequence analysis).
Results: We did not identify systematic trends or grouping of data in the AC protein comparison experiment,
implying low variability between individual proteomic profiles of AC.
In the AC proteome evaluation experiment, we identified 199 proteins. When compared to previously published lists
of proteins identified from CSF and plasma, 15 of the AC proteins had not been reported in either of these
datasets. By a targeted protein identification approach, we identified 11 of these 15 proteins in pooled CSF from
neurologically-normal patients, demonstrating that the majority of abundant proteins in AC fluid also can be found
in CSF. Compared to plasma, as many as 104 proteins in AC were not found in the list of 3017 plasma proteins.
Conclusions: Based on the protein content of AC fluid, our data indicate that temporal AC is a homogenous
condition, pointing towards a similar AC filling mechanism for the 14 patients examined. Most of the proteins
identified in AC fluid have been identified in CSF, indicating high similarity in the qualitative protein content of AC
to CSF, whereas this was not the case between AC and plasma. This indicates that AC is filled with a liquid similar
to CSF. As far as we know, this is the first proteomics study that explores the AC fluid proteome.
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Background
Arachnoid cysts (AC) are benign intracranial lesions
with a reported prevalence in the adult population of up
to 1% [1,2]. AC can be found all along the cranio-spinal
axis, but have a marked predilection for the temporal
fossa [3]. Anatomically, ACs are formed by a splitting of
the arachnoid mater (AM) creating a potential space
that when filled with fluid appears as a cyst [4,5]. Tem-
poral ACs are classified according to Galassi et al. [6].
Briefly, a type I cyst is small, biconvex, and located at
the anterior temporal pole. A type II cyst involves the
proximal and intermediate segments of the Sylvian fis-
sure, and a type III cyst involves the entire Sylvian fis-
sure and has often a marked radiological mass effect.
The cyst wall is composed of non-neoplastic arachnoid
cells with a capacity to secrete fluid [7,8] that slightly
differs in chemical composition from that of cerebrosp-
inal fluid (CSF) [9]. The genetic profile of temporal AC
membranes [10] indicates that these cysts represent a
homogenous condition, but the underlying cause of AC
formation is unknown. Further analyses of the cyst fluid
with proteomics, the large-scale studies of proteins,
might give indications of the aetiology of AC and thus
shed further light on the mechanisms underlying fluid
secretion and transport.
One aim of this study was to compare the protein con-
tent of cyst fluid from temporal AC of different individuals
using proteomics (AC protein comparison experiment).
Our hypothesis was that AC is a homogenous condition,
and that we could identify a similar protein profile from
AC from different patients. Homogenous protein content
between AC fluid from different patients would point
towards similar filling mechanisms for the examined
patients. Large differences in some patients would indicate
different filling mechanisms in these patients. Such a dif-
ference, if present, would be revealed by a label-free pro-
teomics comparison approach. Mass spectrometry-based
label-free approaches are commonly used for semi-quanti-
tative comparison of complex protein samples [11].
Another aim of the study was to identify the major
proteins present in AC fluid and examine if these pro-
teins also appeared in CSF and plasma (AC proteome
evaluation experiment). For the proteins that did not
appear in the CSF and plasma protein databases, we
used a targeted mass spectrometry protein identification
approach referred to as MIDAS in an attempt to identify
these AC fluid proteins in CSF. The protein content of
AC fluid is largely unknown, but it has been shown to
have reduced protein content relative to that of CSF
from the same patient, as evaluated by clinical chemistry
[9]. In a similar study, Sandberg et al. [12] studied the
clinical chemistry of AC fluid in pediatric patients. We
did not have specific hypotheses on the degree of simi-
larity of AC fluid to CSF or plasma, as this has not been
thoroughly demonstrated in literature. This AC fluid
protein identification part of our study and comparison
with CSF and plasma might give information about the
origin of the AC fluid and the mechanisms of filling and
sustaining of AC.
Methods
Participants and collection of AC fluid and CSF
15 patients (six male, nine female, age 22-77 y) with
unilateral, temporal AC were included in the study. AC
fluid was collected during surgery for AC at Haukeland
University Hospital (Bergen, Norway). The patients’
characteristics are summarized in Table 1. One patient
(No. 3) had previously been operated for a chronic sub-
dural hematoma, most probably caused by the cyst [13],
and another patient (No. 4) had undergone previous
surgery for the AC. The other patients had no previous
history of intracranial hematomas or surgery. The sam-
ple collection and handling protocol used in this study
have been described in detail elsewhere [9,14]. Briefly,
AC fluid was collected during elective surgery for AC
(craniotomy with fenestration and extirpation of the
cyst) by puncturing the dura with a 23G, 25 mm long
syringe needle using an Optidynamic® spinal fluid man-
ometer (Mediplast AB, Malmo, Sweden) by siphoning
through a burr hole before the craniotomy/opening of
the dura. This procedure ensures that CSF does not
contaminate the collected AC fluid: The remaining fluid
in the cyst was removed by suction during opening of
the cyst wall. The collected AC fluid was centrifuged at
450 × g for 5 min to remove cells and cell debris, and
the supernatant was aliquoted and frozen at -80°C.
Table 1 Table of arachnoid cyst patients in study, with
age/sex, sidedness, Galassi-stage [6] and remarks.
Patient Age (yrs),
sex
Side Galassi-stage
[6]
Remarks
1 26, f Left 2
2 43, m Left 2
3 58, f Left 3 Old haematoma
4 34, f Left 2 Reoperation
5 22, f Right 1
6 36, f Right 2
7 35, f Right 2
8 77, f Left 1
9 42, f Left 1
10 60, m Left 2
11 56, m Right 2
12 25, m Left 1 Slight observed
haemolysis
13 30, f Left 1
14 37, m Left 2
15 63, m Left 2
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Deviations and observations on individual sample mate-
rial were noted on sampling. During this sampling,
slight hemolysis was observed in one patient sample (No
12). The CSF used for the targeted AC protein identifi-
cation experiment was collected under informed consent
as lumbar CSF before spinal anaesthesia in patients
undergoing lower extremity orthopedic surgery from
neurologically healthy individuals. The CSF was handled
by the same protocol as for the AC fluid, and the CSF
used in this experiment was pooled from 11 individuals.
Ethics
Patients were recruited by the responsible surgeon and
signed a written informed consent. This project was
approved by the Regional Committee for Medical and
Health Research Ethics (REK) of Western Norway
(approvals REK 70.03, NSD 9634, REK 151.06 and REK
2009/1885).
Chemicals
Trypsin was purchased from Promega (Fitchburg WI,
USA). Urea, acetonitrile (ACN), formic acid (FA), cal-
cium chloride (CaCl2), iodoacetamide (IAA) and dithio-
threitol (DTT), potassium phosphate monobasic
(KH2PO4), potassium chloride (KCl), water and trifluor-
oacetic acid (TFA) were purchased from Sigma-Aldrich
(St. Louis MO, USA). Water and ACN were of HPLC
quality.
Sample preparation and protein digestion
The protein concentration in AC fluid was measured
using a Qubit™ fluorometer (Life Technologies, Carls-
bad CA, USA). AC fluid was concentrated and desalted
using Amicon 3 kDa molecular weight cut-off filters
(Millipore, Billerica, MA, USA) and dried in a vacuum
concentrator (Eppendorf, Hamburg, Germany). The pro-
teins were digested into peptides using in-solution diges-
tion, as follows: The dried protein pellet was dissolved
in 6 M Urea and 100 mM DTT and incubated for 1 h
at 37°C. Cysteins were alkylated using 200 mM iodoace-
tamide and the samples were incubated for 1 h at 37°C.
Chymotrypsin activity was inhibited by adding 2 mM
CaCl2 the proteins were digested to peptides over night
using a protein:trypsin ratio of 1:50. Each sample was
acidified using 5% TFA to quench the digestion activity,
followed by drying the sample completely in a vacuum
concentrator.
Strong cation exchange (SCX) chromatography
The samples were dissolved in 120 μL of SCX loading
buffer (5 mM KH2PO4, 25% ACN, 0.05% FA, pH = 3)
and fractionated by SCX chromatography using an Ulti-
mate 3000 LC system (Dionex, Ultimate, Sunnyvale, CA,
USA) equipped with a BioBasic SCX column (150 mm
× 2.1 mm, 5 μm, Thermo Scientific, Ontario, Canada).
The peptides were eluted in SCX elution buffer (500
mM KCl, 5 mM KH2PO4, 25% ACN, 0.05% FA, pH 3.0)
over 55 min with a flow rate of 0.2 mL/min. A total of
28 SCX fractions were collected. The first two fractions
(SCX fraction 1 and 2) were collected with 5.5 min
intervals (first 11 min) and the last fraction (fraction
number 28) was collected over the last 5 min. Fractions
number 3-27 was collected with 1.5 min intervals. After
collection, each SCX fraction was vacuum concentrated
to dryness.
Sample clean-up
The samples were desalted using a 96 well reverse phase
Oasis® HLB μElution Plate 30 μm (Waters, Wilford,
MA, USA). The wells in the μElution plate were condi-
tioned with solvent B (80% ACN, 0.1% FA) and there-
after washed twice with solvent A (0.1% FA). The
peptides were re-suspended in solvent A, added to the
μElution plate, and washed thrice with solvent A before
the peptides were eluted twice using solvent B. One-
minute centrifugation at 200 × g was used for all centri-
fugation steps except for addition of sample where 3
min at 150 × g was used. The samples were concen-
trated to dryness under vacuum and frozen at -80°C
prior to mass spectrometry (MS) analysis.
Mass spectrometry
In the AC protein comparison experiment, the peptides
were dissolved in 0.1% FA, and 4 μL (1.6 μg) of the
sample was injected onto a 40nL enrichment column
(Zorbax 300SB C18 5 μm, Agilent Technologies, Santa
Clara, CA, USA) at a flow rate of 3 μL/min using 3%
ACN, 0.1% TFA. The separation column (0.0075 × 43
mm Zorbax 300SB C18 5 μm, Agilent Technologies)
was used with the following gradient and a flow rate of
300 nL/min using solvent A (0.1% FA) and solvent B
(90% ACN, 0.1% FA): 3-15% solvent B for 3 min, 15-
45% solvent B for 42 min, 45-90% solvent B for 5 min
and back to 3% solvent B after 5 min. Both columns
were integrated in a CHIP (Agilent Technologies, Santa
Clara, CA, USA), and an 1100 cap/nano HPLC coupled
to a chip-cube-LC/MSD XCT Plus ion trap mass spec-
trometer (Agilent Technologies, Santa Clara, CA, USA)
was used for separation and analysis, respectively. MS
data was acquired using the AutoMS2 mode of the
three precursors with highest intensity active exclusion
for 1 min.
For the AC proteome evaluation experiment, the pep-
tides were dissolved in 0.1% FA and 5 μL of the sample
was injected to the analytical fused-silica capillary col-
umn (15 cm long, 75 μm i.d.) packed with Reprosil-Pur
3 μm C18 resin (Dr. Maisch, Ammerbuch-Entringen,
Germany). The settings for LC were: Trap column: 2%
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ACN, 0.1% FA with a flow rate of 25 μL/min. Analytical
column: solvent A was 0.1% FA and solvent B was 90%
ACN, 0.1% FA. The flow rate was 0.288 μL/min with
the following gradient: 5-12% solvent B for 2 min, 12-
30% solvent B for 48 min, 30-50% solvent B for 20 min,
50-95% solvent B for 1 min and 95% solvent B was kept
constant for 5 min before regeneration of the column
for 24 min. The nano-HPLC system (Dionex, Ultimate,
Sunnyvale, CA, USA) was coupled to an Ultima Global
ESI-Q-TOF mass spectrometer (Waters, Wilford, MA,
USA). The scan area for the MS survey scan was m/z
300-1500 with automatic fragmentation of the three
ions with highest intensity. All the data was acquired in
data dependent mode.
For the targeted AC protein identification experiment,
the tryptic peptides of CSF from neurologically normal
patients were dissolved in 0.1% FA and 1 μL was
injected into the Q-TRAP 5500 (AB Sciex, Foster City,
CA, USA) coupled to a nano-HPLC system (Dionex,
Ultimate, Sunnyvale, CA, USA). The targeted mass spec-
trometry analysis was done using the MIDAS (Multiple
Reaction Monitoring (MRM) initiated detection and
sequence analysis) workflow [15] selecting a minimum
of 3 peptides per protein, and three transitions per pep-
tide based on information from in silico digestion. The
instrument settings were 15 ms dwell time with approxi-
mately 3.5 s cycle time for 100 transitions per method in
four analyses. MRM was then used as a survey scan in
information dependent acquisition (IDA) to detect spe-
cific peptide peaks, and each resulting MRM peak was
examined by two full MS/MS-scans to obtain sequence
verification of the hypothesized peptide.
Mass spectrometry data analysis
For the AC protein comparison experiment, the raw data
was processed with the Spectrum Mill search engine
(Rev A.03.03.084) (Agilent Technologies, Santa Clara,
CA, USA) using Carbamidomethylation (C) as fixed
modification. The precursor mass tolerance was set to
2.5 Da with a product mass tolerance of 0.7 Da, and
two trypsin miss-cleavages were allowed. The default
autovalidation settings were applied for both protein
and peptide level validation. Briefly, peptides were
accepted at charge +2 if score >11 and%SPI >60 and at
charge +3 if score >13 and%SPI >70. Proteins with a
score >20 were accepted. A threshold of 2 was set both
for peptides and proteins for the forward-reverse score
and the rank 1-2 score, except for charge +2 with score
>6 and%SPI > 90 where the threshold was 1.
For the AC proteome evaluation experiment, the mass
list was extracted into PKL files with Masslynx (Waters,
Wilford, MA, USA) and the PKL files were merged into
a single MGF file using PklFileMerger [16]. All MS/MS
data were searched using the MASCOT (version 2.2.2)
software platform (Matrix Science, London, UK) against
the IPI-human database (v3.69, 174784 entries). Missed
cleavages were set to one using trypsin as the enzyme.
Carbamidomethyl (C) was set as fixed modification
whereas Oxidation (M) was set as variable modifications.
The peptide tolerance was set to 40 ppm and the MS/
MS tolerance was set to 0.6 Da. Protein organization
and redundancy reduction was done using the Scaffold
software (v3.00.02 [17]). Peptide and protein identifica-
tions were accepted when the probability of correct
identification was greater than 95%, with a minimum of
two identified peptides per protein.
To verify peptide specificity in designated protein tar-
gets in the targeted AC protein identification experiment,
MS/MS spectra were extracted using Analyst software
(version 1.5) (Life Technologies, Carlsbad CA, USA).
The selected spectra were searched using the MASCOT
(version 2.3.0) software platform (Matrix Science)
against the IPI-human database (version 3.78, 302626
entries) using precursor mass and MS/MS tolerance at
0.2 Da. Carbamidomethyl (C) was set as fixed modifica-
tion and 0 miss cleavages were chosen.
The protein list from the AC fluid pool created in the
AC proteome evaluation experiment was compared to
published proteome libraries of CSF [18] and plasma
[19]. Database comparison was performed using Protein-
Center, v3.2.0.9 (Proxeon, Odense, Denmark). The
grouping of proteins and analysis of molecular function
and biological processes was performed in ProteinCen-
ter, where gene ontology terms linked to specific pro-
teins are obtained using mappings from the Gene
Ontology Consortium website [20].
Statistical methods
Principal component analysis (PCA) is a mathematical
method that transforms a number of possibly correlated
variables into a smaller number of uncorrelated variables
called principal components, with the objective of
improved understanding of the data [21]. The algorithm
of PCA gives the weight of each principal component,
meaning the percentage of variation in the dataset
explained. In the AC protein comparison experiment, the
protein content between individual samples was com-
pared based on spectral intensities. The spectral intensi-
ties in each sample were normalized based on the total
sum of all intensities in that sample relative to a chosen
reference samples. The protein hits from the AC protein
comparison experiment were sorted according to protein
score. To check for possible outliers, we first did a PCA
including all identified proteins in the analysis, and
plotted the patients according to the two first principal
components. Next, we compared the samples based on
the 50 proteins with highest protein score to avoid large
influence from proteins identified in a low number of
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samples. Finally, we used a sub-sampling scheme [22,23]
consisting of two steps:
1 - select 50 proteins at random and measure the dis-
tance normalized to standard deviation from the origin
of each patient and 2 - repeat the first step 1000 times,
and calculate the average distance from the origin over
the 1000 replications.
This analysis was designed to reveal the degree to
which any particular sample is divergent from the rest.
Statistics was performed in the statistical software pack-
age R, version 2.11.1. (The R Foundation for Statistical
Computing, Vienna, Austria).
Results
A flow chart of the two main experiments conducted in
this study, the AC protein comparison experiment and
the AC proteome evaluation experiment is given in
Figure 1.
The AC protein comparison experiment
In the AC protein comparison experiment the protein
contents of AC fluid from 14 patients (patients 1-14)
were semi-quantitatively compared using a label-free
proteomics approach to determine the protein homoge-
neity across the different patients. The peptides from
each of the 14 patients were analyzed on an ion-trap
mass spectrometer, and the protein extracted ion chro-
matographic (XIC) intensity values, extracted from the
Spectrum Mill searched data, were compared between
the different patients using PCA. In total, 139 proteins
were identified from the 14 different patients. When all
139 proteins were compared using PCA, the two first
principal components (PC) explained 33% of the total
variation in the dataset (Figure 2). As low scoring pro-
teins with few associated spectra can lead to more inac-
curate semi-quantitative measurements, we also
compared the 50 proteins with highest protein scores.
For this dataset, the two first PCs explained 48% of the
total variation in the dataset (Figure 3). This was a lar-
ger degree of explained variation than the model based
on all 139 proteins. A comparison based on the 50 high-
est scoring proteins gave a clearer separation in absolute
distance from the origin for samples from patients 3
(old hematoma), 4 (previous operation) and 12 (slight
observed hemolysis), as well as possibly patient 9, than
for the other patients. To check whether or not this
separation was due to a single or a few proteins, we per-
formed a sub-sampling scheme. Selecting 50 of the 139
proteins at random for 1000 iterations and evaluating
absolute distance in standard deviations from the origin
showed that patients 3, 4 and 12, the samples presumed
to be different, are consistently further away from the
sample mean than the rest of the patients (Table 2),
while this was not the case for patient 9. Disregarding
patients 3, 4 and 12, the dataset of individual patient’s
AC fluid samples presents little systematic variation. We
Figure 1 Flow charts of the experimental procedure for the
arachnoid cyst protein comparison experiment and for the
arachnoid cyst proteome evaluation experiment.
Figure 2 Arachnoid cyst protein comparison experiment (all
proteins). Principal component analysis (PCA) of individual AC fluid
LC-MS/MS results, normalized to sample sum. The figure is based on
evaluation of all 139 proteins. Axis labels are weights of axes and
the amount of total variance explained by the PC. The percentage
of variance explained by the first two PCs was 33%. Observe that
patients 3 and 4, as well as patient 12 were apart from the other
patients.
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did not find that a few specific proteins create the
separation of patients 3, 4 and 12 from the others.
There was no apparent sub-grouping or trends in the
data. The lack of systematic trends is an indication of
homogenous sample material, thus suggesting that AC
is a homogenous condition as evaluated by proteomics.
The AC proteome evaluation experiment
In the AC proteome evaluation experiment, the aim was
to identify the major protein components of AC fluid,
and to qualitatively compare these proteins to the pro-
teins previously identified in CSF and plasma and
thereby learn more about the composition and origin of
AC fluid. Based on the results in the AC protein com-
parison experiment, AC fluid from patients with identi-
fied blood protein haemoglobin in the cyst fluid was
excluded from this analysis (patients 7, 12, 13 and 14).
In this experiment, 10 μg AC fluid from the remaining
11 patients was pooled, digested, fractionated using SCX
chromatography, purified and analyzed on a Q-ToF
mass spectrometer. From these analyses, 199 proteins
were identified in the AC fluid (Additional File 1: List of
199 proteins detected in a pool of AC fluid from 11
patients, with number of peptides and sequence
coverage). The identified proteins spanned a large range
of MWs, with apolipoprotein C-I being the smallest
with a MW of 9.3 kDa, and protocadherin fat 2 being
the largest with a molecular weight of 479.3 kDa. The
isoelectric point of the proteins ranged from 4.35 to
9.96, represented by cell growth regulator with EF hand
domain protein 1 and NANUC-1 heavy chain protein,
respectively. The MW and pI calculations were per-
formed using the Compute pI/Mw tool [24]. The 199
identified proteins were compared based on IPI acces-
sion numbers to published libraries of CSF [18] and
plasma [19] (Figure 4). The database comparison identi-
fied 15 proteins that were not reported in CSF or
plasma and we identified 11 of these by targeted protein
identification in lumbar CSF samples using the MIDAS
workflow on a Q-TRAP 5500 mass spectrometer (Table
3). Hence, most proteins identified in AC fluid (195 out
of 199) were proven to also be present in CSF or
plasma. The four proteins that were not found in the
databases were; Isoform 3 of seizure 6-like protein 2,
full-length cDNA clone CS0DD006YL02 of neuroblas-
toma of Homo sapiens, isoform 2 of neuroendocrine
protein 7B2, and cell adhesion molecule 1 (Table 3).
The overlap between AC fluid and plasma only con-
tained 3 supplementary proteins not identified in CSF,
whereas CSF and AC fluid had 89 proteins in common
but not found in plasma (Figure 4). The 199 identified
Figure 3 Arachnoid cyst protein comparison experiment (top
50 proteins). Principal component analysis (PCA) of individual AC
fluid LC-MS/MS results, normalized to sample sum. The figure is
based on evaluation of top 50 proteins on protein score. Axis labels
are weights of axes, the amount of total variance explained by the
PC. The percentage of variance explained by the first two PCs is
48%. Observe that patients 3 and 4, as well as 12 and possibly 9
were apart from the other patients.
Table 2 Arachnoid cyst fluid protein comparison
experiment: distance in dataset standard deviation from
the origin for each patient
Patient All protein
scores -
figure 2
50 highest
protein scores -
figure 3
1000 iterations of 50
randomly-selected
protein scores
1 0.3 0.3 0.5
2 0.7 0.6 0.7
3 2.3 2.2 2.1
4 1.9 1.9 1.8
5 1.6 1.4 1.7
6 0.9 0.7 1.0
7 1.8 0.4 1.3
8 0.2 0.1 0.8
9 0.0 1.7 0.7
10 1.3 1.0 1.2
11 1.8 1.2 1.5
12 2.3 3.0 1.8
13 0.3 0.3 0.5
14 0.3 0.2 0.4
Evaluation of all 139 proteins (Column 2), the top 50 proteins on protein score
(Column 3) and an average over 1000 reiterations of PCA performed on
pulling 50 of the 139 proteins in a random sub-sampling scheme (Column 4).
The table show that the standard deviations of patient 3, 4 and 12 were
higher than for the others. This was not the case for patient 9. The values
represent the distance from each individual patient to the mean of all
patients, using the first two principal components from the PCA. The results
were normalized with respect to sample standard deviations.
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proteins identified in AC fluid were annotated to a
diverse range of biological processes, molecular func-
tions, and sub cellular compartments using the Protein-
Center, v3.2.0.9 software (Proxeon, Odense, Denmark)
(Figures 5 and 6 and 7). Of the 199 proteins we identi-
fied, 39.6% are involved in transport as a cellular activity
(Figure 5), 20.6% are involved in transport activity on
molecular function (Figure 6), 81.9% are annotated as
extracellular proteins, while 66.8% are membranous pro-
teins (Figure 7). A comparison of molecular functions of
the proteins identified in AC and CSF demonstrated a
similar distribution (Figure 8). Ten genes have pre-
viously been found to be differentially expressed in AC
membranes compared to normal arachnoid; NKCC1 [7]
and ASGR1, DPEP2, SOX9, SHROOM3, A2BP1,
ATP10D, TRIML1, BEND5 and NMU [10]. We did not
find the corresponding protein products among the 199
identified proteins in our study.
Discussion
As far as we know, this is the first study of proteomic
evaluation of AC fluid. In the AC protein comparison
experiment we looked for systematic differences or dis-
tributions between AC from different patients. The
hypothesis underlying this experiment was that the pro-
tein profile in AC fluid would be similar between the
examined patients, and this was supported by our data.
This indicates a common filling mechanism and source
for AC fluid in these patients. Previous observations of
left side domination in males as well as a predilection
for the middle cranial fossa do imply a common origin
of AC fluid between patients. One possible method of
formation is a defect during the embryological develop-
ment of the Sylvian fissure [25]. AC could potentially be
two or more conditions or subgroups with different fill-
ing mechanisms but our proteomics data from the dif-
ferent samples of AC fluid did not support this
hypothesis, as no systematic variation in PCA-plots was
Figure 4 Venn-diagram showing the protein IPI-identity
overlaps between arachnoid cyst fluid, previously recorded
CSF [18] and plasma [19]. Each large circle defines the content of
the three individual dataset. The numbers indicate proteins in each
group, the overlap between larger circles indicate the number of
protein identities in common.
Table 3 Proteins in arachnoid cyst fluid not identified in published libraries of CSF [18] or plasma [19], and peptides
identified from targeted identification in samples of normal CSF
IPI
number
Protein name Molecular weight
(KDa)
# peptides identified
in CSF
IPI00178854 Contactin-4 113.454 1
IPI00332887 cDNA, FLJ92887, Homo sapiens protein tyrosine phosphatase, non-receptor
typesubstrate 1 (PTPNS1), mRNA
54.967 4
IPI00218803 Isoform B of Fibulin-1 77.214 7
IPI00855821 NRXN1-alpha 169.913 4
IPI00018276 Isoform 3 of Seizure 6-like protein 2 97.501 ND
IPI00216250 Cell recognition protein CASPR4 145.660 1
IPI00479708 Full-length cDNA clone CS0DD006YL02 of Neuroblastoma of Homo sapiens (human) 41.273 ND
IPI00022418 Fibronectin 262.625 12
IPI00645363 Putative uncharacterized protein DKFZp686P15220 51.725 7
IPI00470716 Isoform 2 of Neuroendocrine protein 7B2 23.730 ND
IPI00003813 Cell adhesion molecule 1 48.509 ND
IPI00435020 Isoform 2 of Neural cell adhesion molecule 1 94.574 6
IPI00384998 Isoform 7 of Neurofascin 150.027 4
IPI00451624 Cartilage acidic protein 1 71.421 3
IPI00219664 Isoform 2 of Myelin-oligodendrocyte glycoprotein 28.179 1
Proteins that were not found in any of the databases or in the targeted identification experiment is indicated by not detected (ND).
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observed (Figures 2, 3). This finding supports previous
experiments performed by clinical chemistry [9] and
mRNA [10]. We observed some variation for patients 3,
4 and 12, which can be explained by patient 3 having an
old hematoma in close proximity and patient 4 pre-
viously operated for the same condition. Patient 12 had
a slight observed haemolysis of the AC fluid. We had
anticipated a change in the proteome as a consequence
of a local trauma and consecutive repair mechanisms.
There was an increase in the percentage variation
explained by the first two PCA components when look-
ing at only the 50 highest scoring proteins compared to
all 139 proteins. This can be explained by the fact that
low scoring proteins often are represented by few
Figure 5 Biological process involvement of the 199 arachnoid cyst fluid proteins identified, denoted in percentage of proteins. Note
that any one protein may be involved in several processes. Observe that 39.6% of the proteins are involved in transport processes. The figure
was made using ProteinCenter, v3.2.0.9.
Figure 6 Molecular functions of 199 arachnoid cyst fluid proteins identified expressed as percentage of proteins. Note that any one
protein may have several functions. Observe that 20.6% of the proteins are involved in transporter activity. The figure was made using
ProteinCenter, v3.2.0.9.
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peptide observations, which will lead to few values for
semi-quantitative measurements, and the uncertainty in
the measurements is increased. Hence, focusing only on
the proteins with the highest protein scores will give a
more accurate picture of the comparison. The method
of sub-sampling was useful for evaluation of the stability
of a result, such as for the evaluation on whether patient
9 was an actual outlier relative to the remaining patient
samples.
The AC proteome evaluation experiment resulted in
the identification of 199 proteins from pooled AC fluid
from 11 patients. In order to identify more AC proteins
than the 199 we found in our study, more extensive
fractionation of the sample material could have been
done, although this is limited by amount of sample
material, as well as use of mass spectrometers with
higher sequencing capacity and sensitivity. Using lumbar
CSF as the basis for comparison with AC fluid is possi-
ble when doing a qualitative protein comparison, as pro-
teins are not expected to disappear during migration
towards the lumbar area. In a quantitative study
between AC fluid and CSF on the other hand, it would
be important to use CSF collected in the temporal fossa
to avoid effects of the rostro-caudal protein gradients.
Of the 199 proteins we identified 15 were not found
among the reported 2627 proteins in the CSF database
[18] or the 3017 in the plasma database [19]. This does,
however, not imply that these proteins are not present
in CSF or plasma, as they may not have been previously
identified and therefore not added to the database or
they could be in the database but under a different
accession number, leading to a mismatching. This may
explain why we identified 11 of the 15 AC fluid proteins
not found in the CSF or plasma databases, in the col-
lected CSF samples, using targeted identification with
the MIDAS workflow. Hence the number of proteins
that potentially are unique to AC fluid was further
decreased to four proteins after this experiment.
The large overlap between AC fluid proteins and CSF
(192 of 199 proteins in common) indicates that CSF is
important in the filling of the AC. There was much less
overlap between identified plasma proteins and AC fluid
proteins, with 104 proteins only identified in AC fluid.
As the identified protein content of AC almost comple-
tely overlapped with the proteins previously identified in
CSF, it was not surprising that the biological function
annotation of the identified AC fluid also corresponded
well with the annotations of the CSF proteins (Figure 8).
We did not observe that any particular protein group
was not present in AC fluid compared to CSF. In addi-
tion small (9.3 kDa), large (479.3 kDa), basic (pI 9.96),
and acidic (pI 4.35) proteins were observed in AC fluid,
indicating that there were no absolute exclusion of pro-
teins with these different characteristics even though the
most extreme basic and acidic proteins were not
observed. Certain protein groups could be expected to
not be present in AC if there was a selective transport
mechanism of fluid across the AC membrane. There
could, however still be quantitative differences between
certain protein groups in CSF and AC fluid, which
would then point towards properties in the filling
mechanism. Given the high qualitative similarity we
found between AC fluid proteins and CSF proteins, a
relevant future study would be to do a quantitative pro-
tein comparison of the temporal fossa CSF and AC fluid
from the same patient collected at the same time. This
Figure 7 Cellular component localization of 199 arachnoid cyst fluid proteins identified, expressed as percentage of proteins. Note
that each protein may be identified in several localizations. 81.9% of the proteins are annotated as extracellular proteins, while 66.8% are
annotated as membranous proteins. The figure was made using ProteinCenter, v3.2.0.9.
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Figure 8 Comparison of proteins in arachnoid cyst fluid and CSF [18]based on molecular function, expressed as percentage of
proteins. Note a large difference in number of proteins detected and used as a basis for creating the figure: 199 proteins in AC and 2627 in
the CSF database. The figure was made using ProteinCenter, v3.2.0.9.
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would give information about which proteins or protein
classes that are differentially expressed between AC fluid
and CSF in proximity to the AC, possibly giving further
indications of the filling mechanism of AC fluid and the
origin of the AC fluid.
Conclusions
The results of this study indicate that AC fluid is homo-
genous between patients when evaluated by protein con-
tent using a label-free semi-quantitative proteomics
approach, a finding supporting results from previous
experiments regarding clinical chemistry and mRNA.
This points towards a similar filling mechanism of the
AC for the examined patients. We found that most pro-
teins identified in AC fluid also could be identified in
CSF, while plasma had fewer proteins in common with
AC fluid. This indicates that CSF has similar properties
to AC fluid. We did not find specific groups of proteins
with given properties absent from AC fluid, but there
could still be different quantitative trends between CSF
and AC fluid. A future quantitative proteomics compari-
son between CSF and AC collected from the same
patients at the same time would reveal this information.
Additional material
Additional file 1: List of 199 proteins detected in a pool of AC fluid
from 11 patients, with number of peptides and sequence coverage.
Proteins are denoted by lead protein IPI accession number.
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